Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
Conditions
Interventions
Palazestrant
Letrozole-matching placebo
+3 more
Locations
85
United States
Clinical Trial Site
Hot Springs, Arkansas, United States
Clinical Trial Site
Santa Barbara, California, United States
Clinical Trial Site
Denver, Colorado, United States
Clinical Trial Site
Peoria, Illinois, United States
Clinical Trial Site
Ames, Iowa, United States
Clinical Trial Site
Scarborough, Maine, United States
Start Date
November 3, 2025
Primary Completion Date
December 1, 2028
Completion Date
January 1, 2032
Last Updated
April 16, 2026
NCT04541381
NCT03137095
NCT07547774
NCT06393374
NCT07040891
NCT06949410
Lead Sponsor
Olema Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions